Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Atezolizumab Immunotherapy Receives FDA Approval for First-Line Treatment of Lung Cancer with High PD-L1 Levels

Atezolizumab Immunotherapy Receives FDA Approval for First-Line Treatment of Lung Cancer with High PD-L1 Levels

On 18 May 2020, the US Food and Drug Administration (FDA) approved the following drug for adults whose tumors have high PD-L1 levels and who have metastatic (stage 4) non-small cell lung cancer (NSCLC), for first-line treatment: atezolizumab (Tecentriq). Conditions of use require PD-L1 to stain ≥ % 50 of tumor cells [TC ≥ 50%], or tumor-infiltrating immune-system cells in ≥ % 10 of the tumor area must stain for PD-L1 [IC ≥ 10%], and there must be no EGFR or ALK genetic alterations.

At the same time, the FDA also approved the VENTANA PD-L1 (SP142) Assay as a companion diagnostic device to select patients with NSCLC for atezolizumab treatment.

The IMpower110 Study

The efficacy of atezolizumab was evaluated in IMpower110, a multicenter, international, randomized, open-label trial in patients with stage 4 NSCLC whose tumors were PD-L1-positive (TC ≥ % 1 or IC ≥ % 1). Until disease progression or unacceptable side effects, patients received either 1200 mg of atezolizumab every 3 weeks or platinum-based chemotherapy, with patients randomized 1:1 between the two arms. The primary efficacy outcome was overall survival.

Results

atezolizumab as first-line treatment in non-small cell lung cancer impower 110 study
  • A statistically significant improvement in overall survival was found among patients with high tumor PD-L1 levels who received atezolizumab compared with those treated with platinum-based chemotherapy.
  • Median overall survival was 20.2 months in the atezolizumab arm and 13.1 months in the chemotherapy arm.
  • Starting atezolizumab as the initial treatment in this patient group was found to reduce the risk of death by 41% compared with chemotherapy.
  • There was no significant difference in overall survival at interim or final analyses for the other two PD-L1 subgroups (TC ≥ % 5 or IC ≥ % 5; and TC ≥ % 1 or IC ≥ % 1).
  • Median progression-free survival (PFS) was 8.1 months in the atezolizumab arm and 5 months in the platinum-based chemotherapy arm.
  • The overall response rate was 38% with immunotherapy and 29% with chemotherapy.

The most common (> % 20) adverse event with single-agent atezolizumab in IMpower110 was fatigue/asthenia.

The recommended atezolizumab dose for NSCLC is 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks, administered as an intravenous infusion over 60 minutes.

*

Sources

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression.
fda.gov - 18 May 2020

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Atezolizumab Immunotherapy Receives FDA Approval for First-Line Treatment of Lung Cancer with High PD-L1 Levels

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy